| Barchart Demo Center |
$38.30
+0.01 (+0.03%)
as of 13:45 EST
as of 13:45 EST
Sangamo and Pfizer Announce Updated Phase 1/2 Results
BusinessWire via COMTEX - Sat Dec 07, 09:00AM EST
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE), today announced updated follow-up results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy in patient(full story)
After Yesterday's Decline of 1.10%, Pfizer Inc Offers
Comtex SmarTrend(R) via COMTEX - Tue Dec 03, 12:57PM EST
Pfizer Inc (NYSE:PFE) traded in a range yesterday that spanned from a low of $37.84 to a high of $38.05. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $38.25 on volume of 693,000 shares. O(full story)
PFE: 38.30 (+0.01)
Pfizer Inc Falls 1.10% on Heavy Volume: Watch For
Comtex SmarTrend(R) via COMTEX - Tue Dec 03, 12:57PM EST
Pfizer Inc (NYSE:PFE) traded in a range yesterday that spanned from a low of $37.84 to a high of $38.05. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $38.25 on volume of 693,000 shares. O(full story)
PFE: 38.30 (+0.01)
NavaDerm Partners adds Dan Wechsler as Executive
PR Newswire via COMTEX - Mon Dec 02, 11:15AM EST
NavaDerm Partners ("NavaDerm" or the "Company"), a Northeast-focused dermatology services company and portfolio company of BelHealth Investment Partners ("BelHealth"), a New York-based healthcare private equity firm, announced the(full story)
Pfizer Invites Public to Listen to Webcast of Pfizer
BusinessWire via COMTEX - Wed Nov 27, 10:00AM EST
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical, and Michael Vincent, Senior Vice(full story)
PFE: 38.30 (+0.01)